US Deal Activity is Providing Investors with New Opportunities to Deploy Capital
| By Cecilia Prieto | 0 Comentarios

U.S. equities maintained their upward trajectory in February as the S&P 500 breached 5,000 for the first time. Building upon January’s momentum, the S&P 500 delivered its best two-month performance to start a year since 2019.
Playing a pivotal role in this sustained performance were several of the mega-cap tech companies often referred to as the “Magnificent 7”, notably Nvidia (NVDA), Amazon (AMZN), and Meta (META). Their earnings were bolstered by tailwinds in artificial intelligence, accelerated growth trajectories, and strategic initiatives aimed at enhancing shareholder value.
While the Federal Reserve is unlikely to raise rates further, the timing and pace of potential rate cuts remain uncertain. Federal Reserve Governor Christopher Waller stated that he would require “at least another couple of months” of data to determine if inflation has sufficiently moderated to justify interest rate reductions. The Fed will persist in monitoring incoming data and progress towards achieving their 2% inflation target. Despite investor eagerness for imminent interest rate cuts, initiating them prematurely could potentially lead to a resurgence of inflation.
The Russell 2000 outperformed the S&P 500 in February, but remains below its all-time high set in November 2021. We anticipate a favorable environment for smaller companies in 2024 as post-peak rates and necessary consolidation in certain industries like media, energy and banking should lead to a more robust year. M&A activity began the year strong, setting the stage for catalysts to emerge within our portfolio of companies.
Merger arbitrage performance in February was bolstered by deals that made significant progress towards completion. Immunogen, a biotechnology company developing targeted therapies to treat cancer, was acquired by Abbvie in February for $31.26 cash per share, or about $9 billion. Shares of Immunogen traded at a 6% discount to deal terms days before the deal closed, reflecting the uncertainty over whether the US FTC would launch a phase 2 antitrust investigation, but the FTC approved the deal and it subsequently closed on February 13.
Deal activity was vibrant in February, giving investors many new opportunities to deploy capital including: Masonite’s $4 billion deal to be acquired by Owens Corning, Catalent’s $16 billion deal to be acquired by Novo Holdings, Cymabay Therapeutics’ $4 billion deal to be acquired by Gilead, and Everbridge’s $2 billion deal to be acquired by Thoma Bravo. Deal activity in 2024 has improved compared to 2023, and attractive spreads on deals have created additional opportunities to generate absolute returns.
February was a relatively good month for the convertibles market. With a few notable exceptions, many companies reported earnings and issued guidance that was better than anticipated moving underlying equities higher. Additionally, there has been a bid for convertibles that will need to be refinanced in the coming year. In some cases, this has been from the issuer themselves, but we have also seen a number trade higher in anticipation of a refinancing round. Issuance has picked up substantially with many companies coming back to our market to refinance these upcoming maturities. This new paper has largely been attractive, offering higher coupons and a greater level of equity sensitivity.
Opinion article by Michael Gabelli, managing director at Gabelli & Partners


















